MAGIC Cell-5-Combicytokine Trial

• Status: Unknown status
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Combination use of darbepoetin and G-CSF will improve left ventricular systolic function in patients with acute myocardial infarction who receive intracoronary infusion of mobilized peripheral blood stem cell in comparison with patient who treated with conventional measures and who received intracoronary infusion of mobilized peripheral blood stem cell by G-CSF alone.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Darbepoetin alfa

Criteria

Inclusion Criteria:

• ST elevation acute myocardial infarction

• < 80years

• successful revascularization of culprit vessel

Exclusion Criteria:

• uncontrolled congestive heart failure

• uncontrolled myocardial ischemia

• uncontrolled ventricular arrhythmia

• malignancy

• serious hematologic disease

• chronic renal failure